Insulin is critical for treating diabetes. A diabetic’s pancreas produces none or insufficient insulin, leading to dangerously-high blood sugar. Sedentary lifestyles and unhealthy diets lead to multiple diabetes incidences. This creates huge opportunities for the manufacturers of insulin drugs.
The Asia Pacific insulin market stood around 4, 868 million in 2013. It will be valued approximately USD 15 billion by 2020. Comprehensive portfolio & imminent commercialization of recently-developed products should prove favorable for this market. Penetration of novel insulin products in emerging nations like India and China would also fuel demand.
Full research report on Asia Pacific insulin market analysis:
Patent expiry of leading products (e.g. ‘Lantus’ by Sanofi-Aventis) may create opportunities for local manufacturers. The market is classified according to products, sources, applications, and regions. Products consist of premixed, premixed analogs, rapid acting, short acting, long acting, and intermediate acting.
Long acting, dominating the Asia Pacific insulin market, generated around USD 2, 050 million in 2013. Rapid acting, with high penetration in developed nations, landed second. Analogs and human recombinants are the insulin sources. Analogs held the maximum (81%) shares in 2013. This was credited to untapped markets such as India and China.
Request for sample of this research report:
New products and established brands in emergent & passive regions can also positively impact analogs. Applications are type I & other diabetes and type II diabetes. Type I & other diabetes took in the largest shares (86%) in 2013. The same resulted from high insulin usage in the management of type I diabetes. Advanced insulin drugs also contributed to this segment.
Regions of the Asia Pacific insulin market encompass Japan, Australia, Taiwan, India, New Zealand, China, and South Korea. Other valuable regions comprise Vietnam, Philippines, Indonesia, Thailand, Malaysia, and Rest of Asia Pacific. Japan led the market in 2013. High disposable incomes, patient awareness, and healthcare expenditures produce demand from China.
The region could also be the fastest-growing (CAGR of 21%) market from 2014 to 2020. High diabetes prevalence and lower insulin product prices are likely to be reasons for Chinese expansion. The Asia Pacific insulin market has few sellers. Leading vendors consist of Eli Lilly, Novo Nordisk, and Sanofi Aventis. Participants invest in research & developments for better & more effective products.
View more reports of this category by Grand View Research at:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States